This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of Intracoronary Ad5FGF-4 in Patients With Stable Angina (AGENT-4)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2008 by Cardium Therapeutics.
Recruitment status was:  Active, not recruiting
Information provided by:
Cardium Therapeutics Identifier:
First received: September 10, 2005
Last updated: November 4, 2008
Last verified: November 2008
The purpose of this study is to determine whether a single intracoronary infusion of Ad5FGF-4 is effective in improving exercise capacity measured by exercise treadmill testing, angina functional class, patient symptoms, quality of life, and cardiovascular outcomes. To doses are to be studied, 2.87x10(8) and 2.87x10(9) viral particles, to evaluate the dose-response of Ad5FGF-4. Short-term and long-term safety of Ad5FGF-4 will also be evaluated.

Condition Intervention Phase
Stable Angina Genetic: AdF5FGF-4 vs. Placebo Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multinational Multicenter, Randomized , Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients With Stable Angina

Resource links provided by NLM:

Further study details as provided by Cardium Therapeutics:

Primary Outcome Measures:
  • Treadmill exercise duration [ Time Frame: Week 12 ]

Secondary Outcome Measures:
  • Time to coronary events [ Time Frame: 1 Year ]

Enrollment: 116
Study Start Date: March 2002
Estimated Study Completion Date: November 2008
Primary Completion Date: January 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Genetic: AdF5FGF-4 vs. Placebo
Intracoronary infusion
Experimental: 2
Genetic: AdF5FGF-4 vs. Placebo
Intracoronary infusion
Placebo Comparator: 3
Genetic: AdF5FGF-4 vs. Placebo
Intracoronary infusion


Ages Eligible for Study:   30 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • CCS class II - IV, technically unsuitable for revascularization by CABG or PTCA able to exercise between 3 and 10 minutes on treadmill

Exclusion Criteria:

  • Unstable angina, CCS class 1 angina optimal candidates for revascularization
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00185263

Sponsors and Collaborators
Cardium Therapeutics
Study Director: Paul Foster, MD Cardium Therapeutics, 12255 El Camino Real, Suite 250, San Diego, CA 92130, USA, +1-858-436-1000
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Chief Medical Officer, Cardium Therapeutics Identifier: NCT00185263     History of Changes
Other Study ID Numbers: 305602
Study First Received: September 10, 2005
Last Updated: November 4, 2008

Keywords provided by Cardium Therapeutics:
growth factor
myocardial ischemia

Additional relevant MeSH terms:
Angina Pectoris
Angina, Stable
Chest Pain
Neurologic Manifestations
Nervous System Diseases
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Signs and Symptoms processed this record on June 23, 2017